Holen Sie sich die Stockscreener-App
283.60
0.88%
2.3576
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$281.24
Offen:
$282.42
24-Stunden-Volumen:
221.93K
Relative Volume:
0.13
Marktkapitalisierung:
$55.12B
Einnahmen:
$328.68B
Nettoeinkommen (Verlust:
$2.55B
KGV:
21.76
EPS:
13.0349
Netto-Cashflow:
$1.56B
1W Leistung:
+4.95%
1M Leistung:
+9.25%
6M Leistung:
-17.65%
1J Leistung:
-1.02%
1-Tages-Spanne:
$281.81
$284.76
1-Wochen-Bereich:
$270.64
$284.76
52-Wochen-Spanne:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Firmenname
Cencora Inc
Sektor
Branche
Telefon
610-727-7000
Adresse
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
283.32 | 54.72B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
796.50 | 95.01B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
221.56 | 50.66B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
79.36 | 8.98B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.45 | 1.19B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-29 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-06-03 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-04 | Fortgesetzt | Mizuho | Outperform |
| 2024-09-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-03 | Eingeleitet | Barclays | Overweight |
| 2023-12-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-03-31 | Eingeleitet | Citigroup | Buy |
| 2023-01-31 | Fortgesetzt | Evercore ISI | Outperform |
| 2022-10-11 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-11 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-06-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2022-05-26 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-04-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-12 | Fortgesetzt | Evercore ISI | In-line |
| 2021-02-04 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-02-02 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-01-06 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2021-01-06 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-12-10 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-12-03 | Eingeleitet | Mizuho | Neutral |
| 2020-08-06 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-07-15 | Eingeleitet | Barclays | Underweight |
| 2020-06-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-23 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-04-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-13 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-04-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-11 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2020-02-07 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Hold |
| 2019-07-10 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-04-11 | Eingeleitet | Guggenheim | Buy |
| 2019-04-10 | Herabstufung | BofA/Merrill | Buy → Underperform |
| 2019-04-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-02-11 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-10 | Herabstufung | Jefferies | Buy → Hold |
| 2018-10-26 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-09-20 | Eingeleitet | Berenberg | Buy |
| 2018-07-17 | Fortgesetzt | Stifel | Hold |
| 2018-04-09 | Eingeleitet | MoffettNathanson | Buy |
| 2018-03-12 | Hochstufung | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-12 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-09-25 | Eingeleitet | JP Morgan | Neutral |
| 2017-09-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Cencora Inc Aktie (COR) Neueste Nachrichten
Is Cencora stock underperforming the Nasdaq? - MSN
Cencora Kite Deal Highlights CAR T Growth And Undervalued Share Price Potential - Yahoo Finance
Barclays Cuts Cencora Price Target to $350 From $425, Maintains Overweight Rating - marketscreener.com
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Central Garden & Pet stock (US15135B1017): earnings momentum and pet-care demand in focus - AD HOC NEWS
What Cencora (COR)'s Expanded Role in Kite CAR T Distribution Means For Shareholders - simplywall.st
Cencora hits 52-week low after guidance cut - MSN
Is Cencora Stock Underperforming the Nasdaq? - Barchart.com
Cencora, Inc. (COR) Stock Analysis: Strong Buy Ratings and 29.74% Potential Upside Spark Investor Interest - DirectorsTalk Interviews
A Look At Cencora (COR) Valuation After 2026 Guidance Update And New CAR T Distribution Deal - simplywall.st
Cencora shares fall 2% on second quarter earnings miss - Investing.com
Deals tracker: Tennessee senior care operator spends $50M for 5 facilities - Modern Healthcare
Cencora's Specialty Supply Chain: Where COR's Growth Is Headed - Yahoo Finance
Cencora (COR) Up 5.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street Analysts Predict a 33.55% Upside in Cencora (COR): Here's What You Should Know - Yahoo Finance
Cencora Q2 FY2026 slides: strategic moves amid revenue miss - Investing.com
Earnings Flash (COR) Cencora, Inc. Reports Q2 Revenue $78.36B, vs. FactSet Est of $81.09B - marketscreener.com
Earnings Flash (COR) Cencora, Inc. Posts Q2 Adjusted EPS $4.75 per Share, vs. FactSet Est of $4.82 - marketscreener.com
Cencora shares fall 2% on second quarter earnings miss By Investing.com - Investing.com Nigeria
Cencora cuts revenue growth forecast on slower US sales - marketscreener.com
Earnings call transcript: Cencora Inc. Q2 2026 misses estimates, stock drops - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cencora, Inc.COR - PR Newswire
Cencora Inc. stock (US15135B1017): shares steady as guidance raised and buyback expanded - AD HOC NEWS
Cencora shareholders elect directors and approve key proposals at annual meeting - Investing.com
Cencora (COR) Has a Specialty-Distribution Moat That Looks Stronger Than Its Thin Margins Suggest - AlphaStreet
Cencora Inc. stock (US15135B1017): new Kite CAR T-cell distribution deal highlights specialty focus - AD HOC NEWS
Cencora-Kite Agreement Signals CGT Commercialization Shift - Pharmaceutical Commerce
Cencora Inc stock (US03073E1055): shares steady ahead of next earnings after recent legal headlines - AD HOC NEWS
Billions spent, a new CFO, and a bold vision: Cencora is transforming healthcare from Conshohocken - MSN
Is Cencora’s New CFO, $2 Billion Buyback, and Lawsuit Trio Altering The Investment Case For Cencora (COR)? - Yahoo Finance
Cencora Inc. stock outperforms competitors despite losses on the day - MarketWatch
Cencora Inc. stock (US15135B1017): shares ease while investors digest new corporate responsibility r - AD HOC NEWS
Cencora, Inc. (COR) Stock Analysis: Evaluating a 32% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Cencora Inc. stock (US15135B1017): steady trading as NYSE healthcare distributor holds fiscal 2026 E - AD HOC NEWS
Insider Spends US$1.1m Buying More Shares In Cencora - simplywall.st
Cencora Appoints Eva Boratto as CFO and Reaffirms 2026 Financial Guidance - Minichart
Cencora appoints Eva Boratto as CFO, reaffirms guidance - MSN
Cencora Inc. stock (US15135B1017): new CFO appointment and 2026 EPS guidance reaffirmed - AD HOC NEWS
Assessing Cencora (COR) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st
Cencora, Inc. (COR) Appoints New CFO and Reaffirms Financial Gui - GuruFocus
Eva C. Boratto named Cencora Executive VP & CFO as James F. Cleary to retire - TradingView
Cencora (NYSE: COR) hires new CFO Eva Boratto and reaffirms 2026 and long-term EPS targets - Stock Titan
Insider Buying: Dermot Durcan Acquires Shares of Cencora Inc (CO - GuruFocus
Cencora director D. Mark Durcan buys $1.07m in stock By Investing.com - Investing.com Canada
Cencora director D. Mark Durcan buys $1.07m in stock - Investing.com
Cencora Insider Bought Shares Worth $1,065,040, According to a Recent SEC Filing - marketscreener.com
Director Dermot Durcan adds 4,000 Cencora (NYSE: COR) shares - Stock Titan
Cencora Inc. (COR) Holds Steady Near Support as Neutral Trading ContinuesBull Pennant - thelegaladvocate.com
Cencora Inc. stock (US15135B1017): shares react to investor investigations after guidance reaffirmat - AD HOC NEWS
Finanzdaten der Cencora Inc-Aktie (COR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.89%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):